Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Organovo Holdings, Inc. (ONVO)

Add ONVO Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 10/23/2017 8:40:08 AM - Followers: 315 - Board type: Free - Posts Today: 1


     Organovo is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications.
The company's NovoGen three-dimensional bioprinting technology is a platform that works across all tissue and cell types.
Organovo's NovoGen MMX Bioprinter was selected as one of the "Best Inventions of 2010" by TIME Magazine.
Organovo is helping pharmaceutical partners develop human biological disease models in three dimensions that enable therapeutic drug discovery and development.
Organovo's bioprinting technology can also be developed to create surgical tissues direct therapy.
Organovo leads the way in solving complex medical research problems and building the future of medicine.


ONVO Security Details Share Structure

Shares Outstanding 77,816,787 a/o Mar 16, 2014
Float 50,000,000 a/0 May24,2014
Authorized Shares 150,000,000 a/o May24, 2014

IR and Media Contacts:
Investor Relations Contact:
Media Contact:

Mailing Address:
Organovo, Inc.
6275 Nancy Ridge Drive, Suite 110
San Diego, CA 92121
Phone: 1-858-550-9994

For all the latest company information, details, news, please visit

Organovo's Scientific Founder and Chief Scientific Officer, Dr. Gabor Forgacs
is the Executive and Scientific Director of the Shipley Center for Innovation at Clarkson University and the George H. Vineyard Professor of Biological Physics at the University of Missouri.
He developed Organovo's breakthrough organ printing technology while leading a team of top regenerative medicine scientists from multiple universities, with the backing of a $5MM National Science Foundation Grant.
Professor Forgacs is the author of more than 150 peer reviewed journal articles and the textbook Biological Physics of the Developing Embryo, (with Stuart Newman), published by Cambridge University Press.
He holds a PhD in theoretical physics from the Roland Eotvos University, Budapest Hungary. He moved to the United States in the 1980's from the Institute of Physics of the French Atomic Energy Agency in Saclay to accept a professorship at Clarkson University. 
University of Missouri researcher doing groundbreaking work in regenerative medicine. Here is a video:


Organovo strives to advance regenerative medicine to new heights, by enabling bioprinting tissues and 3-D cellular constructs that were not possible before.
The novel and flexible capabilities of the bioprinting technology allow researchers to generate data faster and more efficiently, thus leading to cutting edge scientific findings, publications, and grants.

Organovo's 3-D NovoGen bioprinting technology allows for the placement of cells in any pattern desired.
First, small building blocks of any shape are created from the desired cell type.
Second, these pre-formed cell aggregates are loaded into a print cartridge that is then attached to the bio-printer.
The bioprinter deposits the cell aggregates one layer at a time, creating multiple stacked 2-D patterns.
A non-invasive gel is placed next to the cell aggregates to hold the desired 3-D shape as each layer is placed in 2-D.

After printing, the cell aggregates retain enough cellular mobility for them to flow into one another, creating a fused tissue construct.
The principles of developmental biology, including cellular self-assembly, allow the final construct to mature into the desired shape and properties.


World class support for NovoGen MMX

The NovoGen MMX Bioprinter™ is supported by our scientific and engineering team.
Every customer receives bioprinter training and access to Organovo's scaffold-free proprietary bioprinting process, which includes cell preparation to tissue maturation.
Additional consultation and application support are available upon request. Organovo's success comes from enabling our customers' success.  


NovoGen MMX Bioprinter

    The NovoGen MMX Bioprinter™ is a novel hardware and software platform at the forefront of bioprinting research and development. The NovoGen MMX™ was developed to meet challenges in biological research.
The platform takes primary or other human cells and shapes them into 3D tissue, with tremendous cellular viability and biology that is superior to even an animal model.
The platform is being used by Organovo's Pharma partners today to enable cutting edge research into drug discovery.

By allowing creation of three dimensional biological structures, Organovo creates functional human tissue that is superior to current disease models.
By enabling printing of tissue in a laboratory environment, investigations on the constructs can be integrated into your current analysis methods. (at 28 sec into the video is a full frontal view of the ONVO NovaGen MMX Bioprinter)

Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ONVO News: Organovo Presents New Preclinical Data on 3D Bioprinted Human Liver Tissues for the Treatment of Inborn Errors of Metabolism ... 10/20/2017 08:05:00 AM
ONVO News: Organovo Announces Release Date for Fiscal Second-Quarter 2018 Financial Results 10/19/2017 08:05:00 AM
ONVO News: Current Report Filing (8-k) 10/04/2017 05:07:12 PM
ONVO News: Organovo Announces Preliminary Fiscal Second-Quarter Total Revenue; Company Restructures to Improve Operational Efficiency 10/04/2017 05:05:00 PM
ONVO News: Statement of Changes in Beneficial Ownership (4) 08/28/2017 04:40:29 PM
#10055   I just took notice of this stock. Sounds drlord10 10/23/17 08:40:07 AM
#10054   Only unrealized gain and unrealized loss but still bigideaportugal 10/21/17 08:10:45 AM
#10053   Greed never wins, my friend.. Rode this to CaptHowdy 10/21/17 07:23:40 AM
#10052   * * $ONVO Video Chart 10-20-17 * * ClayTrader 10/20/17 05:10:54 PM
#10051   UnFREAKINbelievable!!! Been in this CHIT since 2013 $1.99 bigideaportugal 10/12/17 03:08:09 PM
#10050   Holy moly, under a buck and a half! RandolRocketman 10/12/17 02:18:34 PM
#10049   Better yet, get the subsidies that he does. flick 10/11/17 02:31:16 PM
#10048   Agreed with everything except your event horizon. I RandolRocketman 10/11/17 10:10:30 AM
#10047   Thanks. Makes sense. I agree with morley480 10/11/17 09:59:54 AM
#10046   some funds have rules on minimum price, and Northrock 10/10/17 05:57:54 PM
#10045   * * $ONVO Video Chart 10-10-17 * * ClayTrader 10/10/17 05:12:24 PM
#10044   With volume too. What do you suppose morley480 10/10/17 04:25:29 PM
#10043   Considerable dip here today. May be a RandolRocketman 10/10/17 03:56:52 PM
#10042   Organovo Announces Preliminary Fiscal Second-Quarter Total Revenue; Company Alvie 10/04/17 06:00:58 PM
#10041   The Competitive Case For Organovo Holdings $ONVO BuckeyeStocks 09/20/17 09:12:00 AM
#10040   ..getting interesting again! From a weak sub 2 ddbl_our_buck 08/31/17 04:26:55 PM
#10039   Organovo Sponsors Pioneering Research With Amgen and Medikine RandolRocketman 08/23/17 01:05:59 PM
#10038   His track record seems smooth if I am TheBigWhale 08/19/17 09:43:43 AM
#10037   Yeah I didn't. LOL rayank 08/18/17 11:00:28 AM
#10036   Why would you punish yourself? RallyTheMarket 08/18/17 10:46:06 AM
#10035   Will be adding at 1.75 Oil Man 2 08/18/17 05:49:55 AM
#10034   Any upcoming catalysts? Might get back in? rayank 08/17/17 04:43:12 PM
#10033   Nonsense. This is a public company. Doesn't make RallyTheMarket 08/14/17 02:37:33 PM
#10032   Oh, I think they are not telling us morley480 08/12/17 10:49:02 AM
#10031   Interesting... Look up Dr. Doris Taylor at the CIMA7 08/12/17 04:44:49 AM
#10030   Oh yes. You are not the only morley480 08/04/17 02:02:05 PM
#10029   The potential of ONVO is in the therapeutic RandolRocketman 08/04/17 01:27:52 PM
#10028   That seems to me a sensible analysis. morley480 08/04/17 12:18:53 PM
#10027   This reminds me a lot of MAKO Surgical pupuguru 08/04/17 11:43:33 AM
#10026   Hey I can't argue with that. I respect adeezl 08/04/17 10:58:31 AM
#10025   Thanks Pupu, rongreen 08/03/17 08:48:29 PM
#10024   Why we are where we $.02.. pupuguru 08/03/17 04:48:21 PM
#10023   just a random guess but thanks Dad for Windbag1014 08/02/17 10:42:38 PM
#10022   The upside potential is tremendous. phytokaiser1 08/02/17 08:05:52 AM
#10021   hm, well maybe, but I've been fortunate to RandolRocketman 08/01/17 09:41:33 PM
#10020   It seems like a regular pump and dump adeezl 08/01/17 06:36:23 PM
#10019   Organovo and UC San Diego Receive $1.7 Million Mr. Nobody 07/31/17 10:05:56 AM
#10018   And some cash rolling. Nice :) RandolRocketman 07/31/17 08:35:25 AM
#10017 RandolRocketman 07/31/17 12:33:58 AM
#10016   I got out at $2.80s but sorry to rayank 07/20/17 01:11:51 PM
#10015   Elton John would know exactly what to say RallyTheMarket 07/17/17 02:00:52 PM
#10014   This type of work between Organovo, Yale, and morley480 07/14/17 11:12:04 AM
#10013   Using Three-Dimensional Bioprinting To Create Vascular Grafts: A rongreen 07/14/17 10:15:09 AM
#10012   Taylor Crouch, from the recent earnings call: rongreen 07/11/17 04:51:03 PM
#10011   Seems to me like this agreement is for phytokaiser1 07/11/17 10:38:16 AM
#10010   Inmed partnered with Altera for skin tissues for bigideaportugal 07/10/17 09:48:38 PM
#10009   There is so much creativity in the world, WHP03 07/09/17 10:19:30 PM
#10008   Interesting.. stuinvest 07/08/17 09:45:22 PM
#10007   whispers, zoom zoom. RandolRocketman 06/22/17 06:44:09 PM
#10006   ...only time will tell if they hit their WHP03 06/17/17 09:58:34 PM